{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/shingles/background-information/risk-factors/","result":{"pageContext":{"chapter":{"id":"e92f0243-b1ac-50d9-a31a-a07a4c61c5a7","slug":"risk-factors","fullItemName":"Risk factors","depth":2,"htmlHeader":"<!-- begin field 72862818-559d-470d-a127-a6b200dc7170 --><h2>What are the risk factors?</h2><!-- end field 72862818-559d-470d-a127-a6b200dc7170 -->","summary":"","htmlStringContent":"<!-- begin item 05af9ccb-aa1a-4db6-b7dd-a6b200dc7180 --><!-- begin field c8ba7b65-066a-4926-8ae4-a6b200dc7170 --><ul><li><strong>Risk factors for shingles include:</strong><ul><li>Increasing age — although shingles can occur at any age, the <a class=\"topic-reference internal-reference\" href=\"/topics/shingles/background-information/prevalence/\">incidence</a> of the disease (and the risk of <a class=\"topic-reference internal-reference\" href=\"/topics/shingles/background-information/complications/\">complications</a>) increases with age. This is thought to result from an age-related decline in virus-specific, cell-mediated immune responses [<a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">Cohen, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">PHE, 2016</a>].</li><li>Immunocompromise — other conditions that change cell-mediated immunity can increase the risk of shingles (and associated <a class=\"topic-reference internal-reference\" href=\"/topics/shingles/background-information/complications/\">complications</a>). These include HIV infection, lymphoproliferative malignancies, immunosuppressive treatment (such as corticosteroids [long-term use] and chemotherapy), and organ transplantation. A retrospective cohort study assessed the incidence rate of herpes zoster in people with a wide set of immunocompromised conditions and in immunocompromise-free people [<a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">Yanni, 2018</a>]:<ul><li>The overall incidence rate of shingles in the immunocompromised cohort was 7.8/1000 person-years, increasing with age from 3.5/1000 person-years in people aged 18–49 years to 12.6/1000 person-years in people aged 80 years and older. The incidence rate in the immunocompromise-free cohort was 6.2/1000 person-years.</li><li>The proportions of post-herpetic neuralgia and other shingles complications were 10.7% and 2.9% in the immunocompromised cohort, and 9.1% and 2.3% in the immunocompromise-free cohort, respectively.</li></ul></li><li>Certain comorbidities, including:<ul><li>Rheumatoid arthritis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">Forbes et al, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">Kawai, 2017</a>].</li><li>Asthma and chronic obstructive pulmonary disease [<a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">Forbes et al, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">Kawai, 2017</a>].</li><li>Chronic kidney disease [<a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">Forbes et al, 2014</a>].</li><li>Depression [<a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">Forbes et al, 2014</a>].</li><li>Diabetes [<a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">Johnson et al, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">Kawai, 2017</a>].</li><li>Systemic lupus erythematosus [<a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">Johnson et al, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">Kawai, 2017</a>].</li><li>Wegener's granulomatosis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">Johnson et al, 2015</a>].</li><li>Malignancies.</li></ul></li><li>Psychological factors — shingles has been linked to physical, emotional, and sexual abuse. Other contributing factors may include financial stress, inability to work, decreased independence, and an inadequate social support environment [<a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">Cohen, 2013</a>].</li><li>Female sex — there is some evidence that women have a greater risk of developing shingles than men [<a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">Cohen, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">Kawai, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">Le, 2019</a>].</li><li>Race/ethnicity — a systematic review and meta-analysis found that black people had almost half the risk of shingles as white people [<a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">Kawai, 2017</a>].</li><li>Statin use — limited evidence suggests that the use of statins may increase the risk of shingles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">Fan, 2019</a>].</li></ul></li><li><strong>In addition to increasing age and immunocompromise, other risk factors for <a class=\"topic-reference internal-reference\" href=\"/topics/shingles/background-information/complications/\">complications</a></strong><strong> of shingles include </strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">Werner, 2017a</a>]<strong>:</strong><ul><li>Severe atopic dermatitis/eczema.</li><li>Herpes zoster of the head and/or neck area.</li><li>Herpes zoster with:<ul><li>Moderate to severe prodromal or acute zoster‐associated pain. </li><li>Severe rash and/or signs of cutaneous dissemination.</li><li>Signs of involvement of the central nervous system.</li><li>Signs of visceral involvement.</li></ul></li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">Johnson et al, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">PHE, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">Werner, 2017a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">Amirthalingam, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">BMJ, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">PHE, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">Yanni, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">Zorzoli, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">CDC, 2019</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">Le, 2019</a>]</p><!-- end field c8ba7b65-066a-4926-8ae4-a6b200dc7170 --><!-- end item 05af9ccb-aa1a-4db6-b7dd-a6b200dc7180 -->","topic":{"id":"012e484d-8c14-5168-bb5d-e5acb7d4571a","topicId":"2969a8ac-cb7f-4569-be79-822e6009081a","topicName":"Shingles","slug":"shingles","lastRevised":"Last revised in October 2020","chapters":[{"id":"eeb1b918-6c05-5340-b348-ce2809516623","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"8ad8b1b2-36bb-5262-ab5a-05763d6e4c7d","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"b1aed669-8481-5315-ab58-4bb18606e360","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"8fef2c66-91dc-57c6-8cd3-4e4eff8d7727","slug":"changes","fullItemName":"Changes"},{"id":"ea603e45-ec07-5201-a182-ebef4c48ef6b","slug":"update","fullItemName":"Update"}]},{"id":"81feec28-1a5d-5a24-9c52-bee13821b03b","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"bb672f83-c2bd-5dd7-9934-78f09729db48","slug":"goals","fullItemName":"Goals"},{"id":"2036bd3f-37bc-5cea-887d-55c3fc68c7cf","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"cc04b460-a0d8-5e8d-b8d0-c044947b4bd6","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"ee3573cb-38d5-5d4c-9c9d-cd274242d964","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"52999d3b-9cce-59c5-b588-1f7ad7de33e2","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"40a91fd6-3c01-5713-85ad-0a5c4379eab9","slug":"nice-quality-standards","fullItemName":"NICE Quality standards"}]},{"id":"04a0af22-814d-5b14-b28c-7916f1772a4d","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"097dfec6-754a-54a8-9d96-44e1c5704248","slug":"definition","fullItemName":"Definition"},{"id":"f20034b1-ae3e-505b-ac16-3e11f2a6653e","slug":"prevalence","fullItemName":"Prevalence"},{"id":"e92f0243-b1ac-50d9-a31a-a07a4c61c5a7","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"b6f8c581-b332-5d26-ba45-ccfb7189a387","slug":"complications","fullItemName":"Complications"},{"id":"012c8f32-e9cf-5897-a695-4c21cd28ae5d","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"81f3feff-d640-5ee2-83fa-af1a4e8b586a","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"56b89dcf-d466-50f3-a8a0-3a9477ef3362","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"01bc96b7-ea05-59b9-963a-16b2722b9367","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"acd9aec2-87d6-5084-bd3a-5c0b1d164ab4","fullItemName":"Management","slug":"management","subChapters":[{"id":"9872f447-6f59-502d-b6cb-a0fae6d2c085","slug":"management","fullItemName":"Scenario: Management"},{"id":"9ecdcc36-4fec-5b60-aa42-2032f2c406a4","slug":"prevention","fullItemName":"Scenario: Prevention"}]},{"id":"929d18e1-e1f0-5d08-8c55-d289b349a9fd","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"4445c1da-4f7a-5f12-a909-0112bbd72453","slug":"antiviral-drugs","fullItemName":"Antiviral drugs"},{"id":"1223613b-f5a6-5da6-a311-275f5d6181b2","slug":"zostavax","fullItemName":"Zostavax"}]},{"id":"67979756-a00f-5f10-a93e-81509b35e1a8","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"625749c2-4e09-57ba-bdee-cd206d8b02d5","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"377ce207-6229-5548-aef7-a637f176a94e","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"19ac0831-d4e2-52c3-b127-e78b1f26fb6f","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"d46d7aff-a113-50d5-afa1-3310aad844d7","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"d23205e9-41c9-5c70-a9f9-5ce3cfae633a","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"cf98894b-c083-59fd-8150-f390845960f1","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"a52b727c-ba28-5973-9e3c-e4882a883593","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"04a0af22-814d-5b14-b28c-7916f1772a4d","slug":"background-information","fullItemName":"Background information"},"subChapters":[]}}},"staticQueryHashes":["3666801979"]}